Proteins at the intersection of circadian rhythms and metabolic dysfunction-associated steatotic liver disease: an 18-protein panel as a novel predictive biomarker set
By
Yiyi Wang
Qilong Zhai
Xuemei Lian
Lei Zhao
May 13, 2026
Clinical Scorecard: A Novel 18-Protein Panel as Predictive Biomarkers Linking Circadian Rhythm Disruption to Metabolic Dysfunction-Associated Steatotic Liver Disease
At a Glance
Category Detail
Condition Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Key Mechanisms Circadian rhythm disruption linked to metabolic dysfunction and liver disease. Target Population Individuals with disrupted circadian rhythms and metabolic disorders. Care Setting Clinical and research settings utilizing accelerometry data.
Key Highlights
Lower Relative Amplitude (RA) is associated with increased prevalence of MASLD. 18 candidate proteins identified as potential biomarkers for RA-related MASLD. High predictive capability of the 18-protein model demonstrated across multiple machine learning techniques. Guideline-Based Recommendations
Diagnosis
Evaluate hepatic steatosis using the fatty liver index (FLI). Consider RA as an independent factor related to MASLD. Management
Lifestyle modifications to optimize circadian rhythm. Limited pharmacological therapies available for MASLD. Monitoring & Follow-up
Utilize wearable technologies to track circadian rhythm and assess MASLD risk. Risks
Increased risk of cirrhosis, hepatocellular carcinoma, and cardiovascular diseases associated with MASLD. Patient & Prescribing Data
Participants with metabolic dysfunction and hepatic steatosis.
Focus on lifestyle changes and circadian rhythm optimization.
Clinical Best Practices
Incorporate RA assessment in routine evaluations for patients at risk of MASLD. Utilize the 18-protein panel for predictive modeling in clinical settings. Related Resources & Content
